Orexo
16.54 SEK -2.71%Be the first to follow this company
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Revenue
638.8M
EBIT %
-17.14 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ORX
Daily low / high price
16.02 / 17.16
SEK
Market cap
574.11M SEK
Turnover
317.31K SEK
Volume
19K
Latest videos
Financial calendar
Interim report
08.05.2024
Interim report
17.07.2024
Interim report
14.11.2024
Annual report
06.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo A/S | 27.8 % | 27.8 % |
Avanza Pension | 6.9 % | 6.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Orexo, Audiocast with teleconference, Q1, 2024
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools